EA201992618A3 - PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND WAYS OF THEIR APPLICATION - Google Patents

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND WAYS OF THEIR APPLICATION

Info

Publication number
EA201992618A3
EA201992618A3 EA201992618A EA201992618A EA201992618A3 EA 201992618 A3 EA201992618 A3 EA 201992618A3 EA 201992618 A EA201992618 A EA 201992618A EA 201992618 A EA201992618 A EA 201992618A EA 201992618 A3 EA201992618 A3 EA 201992618A3
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
ways
application
pharmaceutical compositions
ppar agonists
Prior art date
Application number
EA201992618A
Other languages
Russian (ru)
Other versions
EA201992618A2 (en
EA039771B1 (en
Inventor
Майкл Даунс
Рональд М. Эванс
Артур Клюге
Бхарат Лагу
Масанори Миура
Сунил Кумар Паниграхи
Майкл Патейн
Сусанта Самаждар
Рамеш Сенайар
Тайсуке Такахаши
Original Assignee
Митобридж, Инк.
Дзе Солк Инститьют Фор Байолоджикал Стадиз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Митобридж, Инк., Дзе Солк Инститьют Фор Байолоджикал Стадиз filed Critical Митобридж, Инк.
Publication of EA201992618A2 publication Critical patent/EA201992618A2/en
Publication of EA201992618A3 publication Critical patent/EA201992618A3/en
Publication of EA039771B1 publication Critical patent/EA039771B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)

Abstract

В настоящем изобретении представлены соединения и композиции, которые применимы при повышении активности PPAR. Представленные в настоящем изобретении соединения и композиции применимы для лечения связанных с PPAR заболеваний (например, мышечных заболеваний, сосудистых заболеваний, демиелинизирующих заболеваний и метаболических заболеваний).The present invention provides compounds and compositions that are useful in increasing PPAR activity. The compounds and compositions of the present invention are useful in the treatment of PPAR-associated diseases (eg, muscle diseases, vascular diseases, demyelinating diseases, and metabolic diseases).

EA201992618A 2016-06-20 2016-10-05 Ppar agonists, compounds, pharmaceutical compositions and methods of use thereof EA039771B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662352348P 2016-06-20 2016-06-20

Publications (3)

Publication Number Publication Date
EA201992618A2 EA201992618A2 (en) 2020-03-31
EA201992618A3 true EA201992618A3 (en) 2020-05-31
EA039771B1 EA039771B1 (en) 2022-03-11

Family

ID=69942819

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201992618A EA039771B1 (en) 2016-06-20 2016-10-05 Ppar agonists, compounds, pharmaceutical compositions and methods of use thereof
EA201992619A EA039833B1 (en) 2016-06-20 2016-10-05 Ppar agonists, compounds, pharmaceutical compositions and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201992619A EA039833B1 (en) 2016-06-20 2016-10-05 Ppar agonists, compounds, pharmaceutical compositions and methods of use thereof

Country Status (1)

Country Link
EA (2) EA039771B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060367A1 (en) * 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
WO2014165827A1 (en) * 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists

Also Published As

Publication number Publication date
EA039833B1 (en) 2022-03-17
EA201992618A2 (en) 2020-03-31
EA039771B1 (en) 2022-03-11
EA201992619A3 (en) 2020-05-31
EA201992619A2 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
EA201890776A1 (en) PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR APPLICATION
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
EA201891203A1 (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EA201791874A1 (en) FLUORINATED INHIBITORS OF LYZYLOXIDE-LIKE ENZYME-2 AND THEIR APPLICATION
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
EA201692201A1 (en) CONNECTIONS AND COMPOSITIONS AS AN AGONISTS OF TOLL-LIKE RECEPTOR 7
EA201691516A1 (en) DIHYDROPYRROLOPIRIDINOVYY INHIBITORS ROR-GAMMA
EA201692177A1 (en) CONNECTIONS AND COMPOSITIONS AS AN AGONISTS OF TOLL-LIKE RECEPTOR 7
BR112018069930A2 (en) powder agonists, compounds, pharmaceutical compositions, and methods of using them
MX2017016134A (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease.
EA201692109A1 (en) OPTIONS OF ANTIBODIES TO FACTOR D AND THEIR APPLICATION
EA201990400A1 (en) COMPOUNDS AND COMPOSITIONS AND THEIR APPLICATION
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EA201890449A1 (en) FUMAGILLINUM HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
EA201892203A1 (en) OXABOROLIC COMPLEX ETHERS, THEIR APPLICATION
EA201792571A1 (en) THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN
EA201892265A1 (en) METHODS OF TREATMENT OF OPHTHALMIC DISEASES
MX2022002635A (en) Angiopoietin-like 4 antibodies and methods of use.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
EA201792085A1 (en) MIXED DISULPHIDE CONJUGATES OF THYENOPYRIDINE COMPOUNDS AND THEIR APPLICATION
EA202090266A1 (en) MPO INHIBITORS FOR MEDICAL USE
EA202090270A1 (en) NEW SUBSTITUTED Xanthine Derivatives
WO2016057660A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EA201992618A2 (en) PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND WAYS OF THEIR APPLICATION